ArticlePakistan journal of medical sciences2024
Clinical value of epidermal growth factor receptor mutation testing in peripheral blood of patients with non-small cell lung cancer.
Article in Pakistan journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical value of EGFR mutation testing in peripheral blood of patients with non-small cell lung cancer. Method: This was a retrospective study. A total of 89 patients with non-small cell lung cancer (NSCLC) admitted to Affiliated Hospital of Hebei University between June 2019 and May 2023 were selected, and divided into the wild-type group and the mutant group according to the results of EGFR mutation testing in peripheral blood. Clinic pathological data of patients were collected and compared between the two groups, the correlation between EGFR mutation and the prognosis was analyzed. Result: No statistically significant difference in the mutation rate of EGFR gene was observed between peripheral blood ctDNA and tumor tissue (p=0.879). EGFR mutation in peripheral blood ctDNA was not significantly correlated with sex, age, ethnicity and ECOG score (p>0.05). The EGFR mutation rate was increased in patients with adenocarcinoma compared with that in patient with squamous carcinoma, and in non-smoking patients compared with that in smoking patients, and the differences were statistically significant (p<0.05). The 1-, 2-, and 3-year disease-free survival (DFS) rates were significantly increased in the mutant group compared with those in the wild-type group, respectively (p<0.05). Conclusion: EGFR mutation in peripheral blood and tumor tissues is highly consistent in NSCLC patients. The EGFR mutation rate is higher in adenocarcinoma and non-smoking patients, and the prognosis is better in patients with EGFR mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.